www.verygoodnewsisrael.blogspot.com
http://blogs.jpost.com/users/just-look-us-now
ISRAEL’S MEDICAL ACHIEVEMENTS
Success in trials of arthritis treatment. Israeli biotech Kitov has announced that its KIT-302 treatment for osteoarthritis successfully reduced arthritic pain in UK trials on 152 patients, without risk of heart problems. In fact KIT-302 is the only treatment for both osteoarthritis and hypertension (high blood pressure).
http://jewishbusinessnews.com/2015/12/16/kitov-pharmas-arthritis-drug-meets-main-goal-in-late-stage-study/
Functional human liver cells grown in the Lab. More news of the work of Hebrew University of Jerusalem Professor Yaakov Nahmias (see here, here, here and here). Now he has been able to use the chemical Oncostatin to double the speed of liver cell production outside the body. http://new.huji.ac.il/en/article/28143
Japan turns to Israeli tech to treat radiation disease. Japan’s Fukushima Medical University and Israel’s Pluristem Therapeutics are to develop Pluristem’s PLX-R18 cells to treat acute radiation syndrome (ARS). Radiation continues to spread following the Fukushima nuclear plant disaster.
http://www.timesofisrael.com/japan-turns-to-israeli-tech-to-treat-radiation-disease/
Prize-winning voice technology. Israel’s VoiceITT (see Mar 2014 newsletter) won the 2015 Medica medical app competition in Dusseldorf with its Talkitt platform that translates the speech of people with communication disabilities. Medica is the world’s largest medical trade fair, attracting nearly 5,000 exhibitors from 70 nations.
http://jewishbusinessnews.com/2015/12/10/4-israeli-startups-sweep-international-medical-app-contest/
https://www.youtube.com/watch?v=EwHYKmxwN4w
First implantation of groundbreaking heart device. Israel’s Enopace (see Mar 2013 newsletter) has seen the first operation to implant its new catheter-based neuro-stimulator to treat patients with congestive heart failure. The procedure was performed by Professor Davor Milicic, head of Cardiology at Zagreb Medical University.
http://www.prnewswire.com/news-releases/worlds-first-endovascular-neuromodulation-device-implanted-in-man-for-the-treatment-of-congestive-heart-failure-540696751.html
Breakthrough status for Tardive Dyskinesia treatment. (TY Atid-EDI) The US FDA has granted Breakthrough Therapy Designation status to Israel’s Teva for its SD-809 (deutetrabenazine) treatment of patients with tardive dyskinesia, a hyperkinetic movement disorder affecting about 500,000 people in the USA.
http://www.tevapharm.com/news/teva_announces_breakthrough_therapy_designation_for_sd_809_granted_by_fda_for_the_treatment_of_tardive_dyskinesia_11_15.aspx
Weizmann in joint research for brain therapies. Israel’s Weizmann Institute has entered into a research agreement with India’s Sun Pharma and Spain’s Health Research Institute of Santiago to develop products for treating neurological diseases such as brain stroke and brain cancer. (See also Apr 2015 newsletter)
http://www.thehindu.com/business/Industry/sun-pharma-inks-pact-for-brain-therapies/article7971997.ece
Micro-pancreas can cure diabetes. (TY Atid-EDI) Israel’s Betalin has significantly increased the lifetime of pancreatic beta cells transplanted into diabetics in order to produce insulin. This has been achieved by simultaneously transplanting an Engineered Micro Pancreas (EMP) to sustain the cells.
http://www.globes.co.il/en/article-israeli-startup-aims-to-end-insulin-injections-1001086686
http://www.betalintherapeutics.com/